Astellas Pharma Inc. reported consolidated earnings results for the three and six months ended September 30, 2019. For the six months, the company reported sales of JPY 650.5 billion against JPY 647.1 billion a year ago. Operating profit was JPY 162.2 billion against JPY 126.8 billion a year ago. Profit for the period was JPY 128.5 billion or JPY 68.16 per share against JPY 103.9 billion or JPY 53.20 per share a year ago.
For the second quarter, the company reported sales of JPY 316.3 billion, operating profit was JPY 85.1 billion, profit was JPY 70.0 billion.
The company revised consolidated earnings guidance for the year ending March 31, 2020. For the year ending March 31, 2020, the company expects sales of JPY 1,256 billion compared to previous guidance of JPY 1,224 billion. Operating profit expects to JPY 263 billion compared to previous guidance of JPY 229 billion. Profit for the period expects JPY 210 billion compared to previous guidance of JPY 182 billion. Earnings per share expects to JPY 111.37 compared to previous guidance of JPY 96.51.